<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536937</url>
  </required_header>
  <id_info>
    <org_study_id>POP13778</org_study_id>
    <secondary_id>U1111-1170-3686</secondary_id>
    <nct_id>NCT02536937</nct_id>
  </id_info>
  <brief_title>A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate</brief_title>
  <official_title>An Open-label Two-stage Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To study the effect of mild, moderate, and severe renal impairment on the pharmacokinetics&#xD;
      (PK) of eliglustat.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      To assess the tolerability of eliglustat tartrate given as a single dose in subjects with&#xD;
      mild, moderate, and severe renal impairment in comparison with matched subjects with normal&#xD;
      renal function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration from screening period is approximately 31 days. In stage 1, only&#xD;
      subjects with severe renal impairment and normal renal function will be enrolled. Subjects&#xD;
      with mild and moderate renal impairment may be enrolled in stage 2 if the results in subjects&#xD;
      with severe renal impairment show a substantial effect of reduced renal function on&#xD;
      pharmacokinetics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- Assessment of PK parameter: Maximum plasma concentration observed (Cmax)</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>- Assessment of PK parameter: Area under the plasma concentration (AUC)</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Area under the plasma concentration versus time curve (AUClast)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Apparent total body clearance (CL/F)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Apparent volume of distribution during the terminal phase (Vz/F)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Predicted accumulation ratio (Rac,pred)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Terminal half-life (t1/2z)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Up to 10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>GZ385660 (healthy subjects)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of eliglustat tartrate will be given under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GZ385660 (subjects with mild renal impairment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of eliglustat tartrate will be given under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GZ385660 (subjects with moderate renal impairment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of eliglustat tartrate will be given under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GZ385660 (subjects with severe renal impairment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of eliglustat tartrate will be given under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eliglustat</intervention_name>
    <description>Pharmaceutical form: capsule&#xD;
Route of administration: oral</description>
    <arm_group_label>GZ385660 (healthy subjects)</arm_group_label>
    <arm_group_label>GZ385660 (subjects with mild renal impairment)</arm_group_label>
    <arm_group_label>GZ385660 (subjects with moderate renal impairment)</arm_group_label>
    <arm_group_label>GZ385660 (subjects with severe renal impairment)</arm_group_label>
    <other_name>GZ385660</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
        For renal impaired:&#xD;
&#xD;
          -  Male or female subjects, between 18 and 79 years of age, inclusive.&#xD;
&#xD;
          -  Body weight between 50.0 kg and 125.0 kg inclusive if male, between 40.0 kg and 110.0&#xD;
             kg inclusive if female, body mass index (BMI) between 18.0 and 37.0 kg/m^2, inclusive.&#xD;
&#xD;
          -  Stable chronic renal impairment, as defined by Cockroft-Gault formula.&#xD;
&#xD;
          -  For severe renal impairment: CrCl &lt;30 mL/min.&#xD;
&#xD;
          -  For moderate renal impairment: 30 mL/min ≤CrCl &lt;50 mL/min.&#xD;
&#xD;
          -  For mild renal impairment: 50 mL/min ≤CrCl ≤80 mL/min.&#xD;
&#xD;
        For matched subjects:&#xD;
&#xD;
          -  Male or female subject, between 18 and 79 years inclusive, matched by age.&#xD;
&#xD;
          -  Body weight within 15% of the body weight of the subjects with renal impairment to be&#xD;
             matched and BMI between 18.0 and 37.0 mg/kg^2 inclusive.&#xD;
&#xD;
          -  Matched by cytochrome P450 (CYP) 2D6 predicted phenotype based on genotype.&#xD;
&#xD;
          -  Certified as healthy by a comprehensive clinical assessment (detailed medical history&#xD;
             and complete physical examination).&#xD;
&#xD;
          -  For healthy subjects: CrCl &gt;80 mL/min.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        For renal impairment patients:&#xD;
&#xD;
          -  Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal,&#xD;
             metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if&#xD;
             female) or infectious disease, or signs of acute illness.&#xD;
&#xD;
          -  Active hepatitis, hepatic insufficiency.&#xD;
&#xD;
          -  Acute renal failure (de novo or superimposed to pre-existing chronic renal&#xD;
             impairment), nephrotic syndrome.&#xD;
&#xD;
          -  History of or current hematuria of urologic origin that limits the subject's&#xD;
             participation in the study.&#xD;
&#xD;
          -  Subjects requiring dialysis during the study.&#xD;
&#xD;
          -  Presence or history of drug hypersensitivity, or allergic disease diagnosed and&#xD;
             treated by a physician.&#xD;
&#xD;
          -  If female, pregnancy (defined as positive beta-human chorionic gonadotropin [β-hCG]&#xD;
             blood test), breastfeeding.&#xD;
&#xD;
          -  Any significant change in chronic treatment medication within 14 days before&#xD;
             inclusion.&#xD;
&#xD;
          -  P-gp inhibitors and/or inducers, CYP2D6 and/or CYP3A inducers, and strong and/or&#xD;
             moderate CYP2D6 and/or CYP3A inhibitors. Up to one weak CYP2D6 inhibitor and/or one&#xD;
             weak CYP3A inhibitor are allowed (as defined in The Metabolism and Transport Drug&#xD;
             Interaction Database™ (DIDB).&#xD;
&#xD;
          -  Positive result on any of the following tests: anti-human immunodeficiency virus 1 and&#xD;
             2 antibodies (anti-HIV1 and anti-HIV2 Ab).&#xD;
&#xD;
          -  Pre-existing cardiac disease (current congestive heart failure, recent acute&#xD;
             myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT&#xD;
             syndrome, or use of Class IA (eg, quinidine, procainamide) and Class III (eg,&#xD;
             amiodarone, sotalol) anti-arrhythmic medications.&#xD;
&#xD;
          -  Any subject with CYP2D6 indeterminate or ultra-rapid metabolizer (URM) phenotype.&#xD;
&#xD;
        For matched volunteers:&#xD;
&#xD;
          -  Any history or presence of clinically relevant cardiovascular, pulmonary,&#xD;
             gastrointestinal, hepatic, renal, metabolic, hematological, neurological,&#xD;
             osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or&#xD;
             infectious disease, or signs of acute illness.&#xD;
&#xD;
          -  Presence or history of drug hypersensitivity, or allergic disease diagnosed and&#xD;
             treated by a physician.&#xD;
&#xD;
          -  If female, pregnancy (defined as positive β-hCG blood test), breast feeding.&#xD;
&#xD;
          -  For subjects 50 years old and below: any medication (including St John's Wort) within&#xD;
             14 days before inclusion, or within 5 times the elimination half-life or&#xD;
             pharmacodynamic half-life of that medication, whichever is longest, with the exception&#xD;
             of hormonal contraception or menopausal hormone replacement therapy; any vaccination&#xD;
             within the last 28 days, and any biologics (antibody or its derivatives) within 4&#xD;
             months before inclusion.&#xD;
&#xD;
          -  For subjects above 50 years old: any significant change in chronic treatment&#xD;
             medication within 14 days before inclusion.&#xD;
&#xD;
          -  P-gp inhibitors and/or inducers, CYP2D6 and/or CYP3A inducers, and strong and/or&#xD;
             moderate CYP2D6 and/or CYP3A inhibitors. Up to one weak CYP2D6 inhibitor and/or one&#xD;
             weak CYP3A inhibitor are allowed (as defined in The Metabolism and Transport Drug&#xD;
             Interaction Database™ (DIDB).&#xD;
&#xD;
          -  Positive result on any of the following tests: hepatitis B surface antigen (HBsAg),&#xD;
             anti-hepatitis C virus (anti-HCV) Ab, anti-HIV1 and anti-HIV2 Ab.&#xD;
&#xD;
          -  Pre-existing cardiac disease (current congestive heart failure, recent acute&#xD;
             myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT&#xD;
             syndrome, or use of Class IA (eg, quinidine, procainamide) and Class III (eg,&#xD;
             amiodarone, sotalol) anti-arrhythmic medications.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 28, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eliglustat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

